Using MRD Status to Guide Care after Quad Induction in Myeloma Ims 2025 Myeloma
Francesco Maura, MD, Memorial Sloan Kettering Cancer Center, New York, NY, gives an overview of a study on genomic drivers The BOSS program: improving the safety of bispecific outpatient step-up dosing for multiple myeloma Evidence supporting the use of MRD-guided treatment in multiple myeloma: GEM2014MAIN and AURIGA Interview with Sagar Lonial, MD, FACP from Winship Cancer Institute Of Emory University. Filmed at IMS September 29th, 2023. Global Myeloma Care: Addressing Gaps in Low- and Middle-Income Countries | Craig Cole, MD | #IMS2025 ...